A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice

BACKGROUND: Although the proteasome is a validated anticancer target, the clinical application of its inhibitors has been limited because of inherent systemic toxicity. To broaden clinical utility of proteasome inhibitors as anticancer agents, it is critical to develop strategies to selectively targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Wehenkel, M, Ban, J-O, Ho, Y-K, Carmony, K C, Hong, J T, Kim, K B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389428/
https://www.ncbi.nlm.nih.gov/pubmed/22677907
http://dx.doi.org/10.1038/bjc.2012.243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389428/
https://www.ncbi.nlm.nih.gov/pubmed/22677907
http://dx.doi.org/10.1038/bjc.2012.243

Ejemplares similares